INFO & CONTACTS:  +39 02 2390 1

Thoracic Oncology Unit

Prof. De Braud

Prof. De Braud Filippo

Head

Typology: Clinical Area, Simple Structure

The Thoracic Oncology Unit of the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan is a clinical and translational research unit dedicated to the diagnosis and treatment of thoracic malignancies, with a particular focus on lung cancer, mesothelioma, and thymic tumors. The mission of the team is to offer personalized care pathways based on innovative and integrated therapeutic approaches through a highly specialized and research-oriented multidisciplinary model. 

The clinical activity is structured as follows: 

  • Weekly outpatient clinics for first oncological consultations, dedicated to the initial assessment and management of new patients; 
  • Weekly follow-up clinics, for the monitoring of patients undergoing treatment or in surveillance; 
  • Daily clinics for the administration of oral and intravenous therapies, both standard and experimental, within active clinical trials; 
  • A dedicated clinic for thymic tumors, providing specialized clinical and therapeutic management. 

The unit is an active part of the thoracic multidisciplinary team, which coordinates: 

  • Multidisciplinary consultations for undiagnosed patients, within the CAT (Cancer Accession Team) clinic, for suspected lung cancer cases; 
  • Multidisciplinary case discussions for diagnosed patients, requiring a multimodal therapeutic strategy involving surgery, radiotherapy, oncology, and pulmonology. 

Clinical and translational research is a core component of the unit, with active participation in phase I, II, and III clinical trials for lung cancer, mesothelioma, and thymic tumors. In addition, observational studies are conducted to better understand the biology and evolution of these diseases, with a particular focus on identifying predictive biomarkers, mechanisms of resistance to immunotherapy, and strategies for personalized treatment. 

To schedule a first oncological consultation for thoracic malignancies through the National Health Service (SSN), patients can contact the CUP (Unified Booking Center) at +39 0223901, or book directly at the front desks of the Fondazione IRCCS Istituto Nazionale dei Tumori. 

First oncological consultations are available on the following days and times: 

  • Tuesday afternoon from 2:00 PM to 5:00 PM 
  • Wednesday morning from 9:00 AM to 11:00 AM 
  • Friday morning from 9:00 AM to 11:00 AM 

Patients are advised to bring all relevant medical documentation (e.g., radiological images, histological reports, blood tests, previous specialist opinions) to allow for a comprehensive assessment during the first visit. 

Thoracic oncology consultations are provided promptly through the SSN. For those who prefer, the option of private consultations is also available. 

Medical Oncology Secretariat 1

From Monday to Friday, from 9.00 AM to 5.00 PM. 

Access hours for scientific representatives: by appointment. 

Prof. De Braud Filippo
Head

Dott. Ambrosini Paolo
Professional Collaborator

Dott.ssa Beninato Teresa
Medical Director

Dott.ssa Brambilla Marta
Medical Director

Dott.ssa Corrao Giulia
Professional Collaborator

Dott. Lo Russo Giuseppe
Medical Director

Dott.ssa Mazzeo Laura
Medical Director

Dott. Occhipinti Mario
Medical Director

Dott.ssa Prelaj Arsela
Medical Director

Dott.ssa Proto Claudia
Medical Director

Dott.ssa Romanò Rebecca
Medical Director

Ricercatrice senior:

  • Dott.ssa Monica Ganzinelli 

Infermiera di ricerca:

  • Dott.ssa Andra Diana Dumitrascu

  • Dott.ssa Federica Cusumano

Case Manager:

  • Dott.ssa Miriam Monica Fink 

A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell LungmCancer (NSCLC) with Homozygous MTAP Deleti

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non--Small Cell Lung Cancer

A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab versus Placebo, in Combination with Pembrolizumab, Pemetrexed, and Carboplatin, in First-Line Treatment of Part

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinu

A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab

Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV o

A phase 3, multicenter, randomized, open-label study of ifinatamab deruxtecan (I-DXd), a b7-h3 antibody drug conjugate (ADC), versus treatment of physician’s choice (TPC) in subjects with relapsed small cell lung cancer

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC

A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer

A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homoz

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expressi

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1

A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomi

Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-

Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial

KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable

KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants with Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Studio di fase 3, randomizzato, in aperto, che confronta l'efficacia e la sicurezza di OSE2101 rispetto a docetaxel in pazienti HLA-A2 positivi con carcinoma polmonare non a piccole cellule (NSCLC) metastatico con resist

SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First- Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizum

Cancer Cell-Intrinsic PD-1 and immune-microenvironment boost tumor growth upon immune-checkpoint inhibitors in NSCLC

Trapping circulating tumor cells to develop prognostic biomarkers and novel anti-metastatic strategies in lung cancer “Trap4Cure”

Last update: 22/07/2025

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe